Bank of Montreal
MTNB icon

Bank of Montreal’s Matinas BioPharma MTNB Stock Holding History

Bank of Montreal’s Portfolio MTNB Stock Details MTNB Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2020
Q2 		– Sell
-439
Closed -$182K – 4764
2020
Q1 		$182K Buy
439
+30
+7% +$27.2K ﹤0.01% 2367
2019
Q4 		$697K Buy
+409
New +$355K ﹤0.01% 2477

Other funds holding MTNB

BC
Boxer Capital San Diego, California $2.04B AUM 108.39% 1-Year Est. Return
VC
Vivo Capital Palo Alto, California $1.1B AUM 799.93% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
BBA
Baker Bros. Advisors New York $20B AUM 154.41% 1-Year Est. Return
Two Sigma Investments
Two Sigma Investments New York $138B AUM 41.87% 1-Year Est. Return
Victory Capital Management
Victory Capital Management San Antonio, Texas $178B AUM 37.23% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
Royal Bank of Canada
Royal Bank of Canada Toronto, Ontario, Canada $672B AUM 33.48% 1-Year Est. Return
BCM
Bridgeway Capital Management Houston, Texas $5.69B AUM 60.64% 1-Year Est. Return

Bank of Montreal's MTNB Position: Q2 2020 in Review

Bank of Montreal sold out of Matinas BioPharma (MTNB) in Q2 2020, closing a stake of 439 shares — an estimated $182K sold.

Bank of Montreal first reported a position in MTNB in Q4 2019 and held it in 2 quarters. The position peaked at $697K in Q4 2019. 62 funds tracked by Wall St. Rank hold MTNB as of Q2 2020.

  • Bank of Montreal reported no remaining Matinas BioPharma position as of Q2 2020 after selling out during the quarter.
  • Bank of Montreal sold 439 Matinas BioPharma shares in Q2 2020, an estimated $182K.
  • Bank of Montreal first reported a position in Matinas BioPharma in Q4 2019 and held it in 2 quarters.
  • Bank of Montreal's Matinas BioPharma position peaked at $697K in Q4 2019.
  • 62 funds tracked by Wall St. Rank held Matinas BioPharma as of Q2 2020.

Based on Bank of Montreal's 13F filing for Q2 2020, filed 12 Aug 2020.